Kangmai â…¡ Capsule Treatment Of Lower Extremity Deep Venous Thrombosis In Patients With Clinical Efficacy And Molecular Mechanism Research

Objective: Through the clinical observation and animal experiment, to explore the pathogenesis of Lower limb deep vein thrombus,Further confirmed that Kangmai II Capsule treatment of Lower limb deep vein thrombus of the clinical curative effect and mechanism of action.Methods:By random grouping,61cases of Lower limb deep vein thrombus patients divided into treatment group and control group.The treatment group patients with oral Kangmai Ⅱ Capsule;The Control group patients with oral Mailuoshutongkeli(MLSTKL).To observe the cure rate of two groups of patients, Hemorrheology and blood coagulation function test level of the indicators change. Experimental study on the success of improvement and establish the rat model of deep venous thrombosis Using Kangmai II Capsule Lavage treatment,MLSTKL lavage to contrast,Observe each group rats vascular pathological morphological changes,Using ABC-double antibody sandwich ELISA method to detect the contents of ET-1, IL-6, Using immunohistochemical method to detect protein expression of PAF, NF-kB, Rac1, Rac2,Application of polymerase chain reaction (PCR) to detect the level of NF-kBmRNA, Rac1mRNA, Rac2mRNA.Results:Clinical research:Kangmai Ⅱ Capsule treatment group31cases of patients after treatment,8cases cured,16cases had marked effect,5cases were effective, ineffective in2cases, the total effective rate was93.54%.MLSTKL control group30cases of patients after treatment,Cure6cases,6cases were markedly effective,6cases effective,6no effect, the total effective rate was80%.1.The total effective rate in both groups had significant difference (p<0.05),Show Kangmai II Capsule clinical curative effect of treatment group is better than that of MLSTKL control group.2.Kangmai Ⅱ Capsule treatment group the change of hemorheology indicators are better than the MLSTKL control group, with significant difference (P<0.05).Kangmai Ⅱ Capsule treatment group blood coagulation function test the change of the indicators are better than MLSTKL control group, with significant difference (P<0.05).Experimental study: 1.Experimental study on improvement and establish the rat model of deep venous thrombosis,Making animal models of rats after6hours-after72hours,Gradually appear lower limb swelling, dark red, though less, less waterand other symptoms.After dosing Kangmai II Capsule treatment group of symptoms is obvious.2.HE staining under light microscope microscopic changes. Blank control group:Endothelial cells were fusiform, neat, uniform size, arrange neat membrane in vascular smooth muscle, the intimal surface smooth, level off. With the passage of time,Some stripped to observe vascular endothelial cells,Vascular smooth muscle structure disorder,Blood vessel walls and clearance focal infiltration of inflammatory cells, Tube wall thinning, further thrombus spread to most of the lumen.But after medication, inflammatory cells infiltration decreased significantly, the thrombus partly filled in the lumen,Manufacturing72hours after the animal model of pathological changes of the treatment group than the72hours after the animal model of the control group obviously.3.After making animal models of ET-1content increased gradually over time, he content of ET-1in the72hours after making animal model control group and72hours after making animal model of treatment,Less than72hours after making animal models of blank group,And the treatment group is better than the control group;The content of IL-6with time gradually increased,The content of IL-6in the72hours after making animal model control group and72hours after making animal model of treatment, more than72hours after making animal models of blank group,But the treatment group was significantly lower than the control group, there was statistical significance (p<0.05).4.After making animal models, PAF, NF-kB, Rac1,Rac2protein positive expression with time gradually increased, Positive expression of the protein in the72hours after making animal model control group and72hours after making animal model of treatment,Less than72hours after making animal models of blank group,But the treatment group was significantly lower than the control group, there was statistical significance (p<0.05).5.After making animal models,the level of NF-kBmRNA,Rac1mRNA,Rac2mRNA over time, gradually increase, The genetic level in the72hours after making animal model control group and72hours after making animal model of treatment,Less than72hours after making animal models of blank group,But the treatment group was significantly lower than the control group, there was statistical significance (p<0.05).Conclusion:Clinical observation:1.Kangmai Ⅱ Capsule can improve the patient’s blood coagulation function,Reduce the plasma fibrinogen, plasma D dimer,Can effective treatment for Lower limb deep vein thrombus.2.Kangmai Ⅱ Capsule can improve the patient’s Hemorrheology indicators,Reduce the blood viscosity, reduce high blood coagulation state, state before effective corrective thrombosis, Can effective treatment for Lower limb deep vein thrombus.Animal experiments:1.Experimental study on the success of improvement and establish the rat model of deep venous thrombosis.2.By measuring the content of ET-1,IL-6,Validation of deep vein thrombosis in rats to establish animal model of success.Further validated Kangmai Ⅱ Capsule Capsule by lowering the content of ET-1,IL-6,Can effective treatment for Lower limb deep vein thrombus.3.the level of NF-kBmRNA,Rac1mRNA,Rac2mRNA is rised,Participated in the Lower limb deep vein thrombus,May be the occurrence of Lower limb deep vein thrombus.4.Rac1and Rac2or PAF may through activation of NF-kB,Make the NF-kB activation, resulting in thrombosis,For prevention and treatment of Lower limb deep vein thrombus,provides a new train of thought and way.5.Kangmai Capsule can by lowering the expression of protein of PAF、NF-kB、 Rac1、Rac2,Can effective treatment for Lower limb deep vein thrombus.